| [1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
QI J, LI M, WANG L, et al. National and subnational trends in cancer burden in China,2005-20:an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12):e943-e955.
|
| [3] |
THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554.
DOI
PMID
|
| [4] |
ZHANG Y, VACCARELLA S, MORGAN E, et al. Global variations in lung cancer incidence by histological subtype in 2020:a population-based study[J]. Lancet Oncol, 2023, 24(11):1206-1218.
|
| [5] |
CHAI X, ZHANG X, LI W, et al. Small cell lung cancer transformation during antitumor therapies:a systematic review[J]. Open Med(Wars), 2021, 16(1):1160-1167.
|
| [6] |
SEO H Y, KIM S C, ROH W L, et al. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types[J]. Sci Rep, 2022, 12(1):6345.
|
| [7] |
LIM Z F, MA P C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy[J]. J Hematol Oncol, 2019, 12(1):134.
|
| [8] |
SATO Y, SAITO G, FUJIMOTO D. Histologic transformation in lung cancer:when one door shuts,another opens[J]. Ther Adv Med Oncol, 2022, 14:17588359221130503.
|
| [9] |
FERONE G, SONG J Y, KRIJGSMAN O, et al. FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1/p53 mice[J]. Cell Rep, 2020, 30(11):3837-3850.
DOI
PMID
|
| [10] |
GIACCONE G, HE Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer[J]. Semin Cancer Biol, 2023,94:1-10.
|
| [11] |
OFFIN M, CHAN J M, TENET M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J]. J Thorac Oncol, 2019, 14(10):1784-1793.
|
| [12] |
LEE J K, LEE J, KIM S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas[J]. J Clin Oncol, 2017, 35(26):3065-3074.
|
| [13] |
QUINTANAL-VILLALONGA A, TANIGUCHI H, ZHAN Y A, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation[J]. Cancer Discov, 2021, 11(12):3028-3047.
|
| [14] |
中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版)[J]. 中华医学杂志, 2023, 103(27):2037-2074.
|
| [15] |
YATABE Y, DACIC S, BORCZUK A C, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer[J]. J Thorac Oncol, 2019, 14(3):377-407.
DOI
PMID
|
| [16] |
POON I K, CHAN R C K, CHOI J S H, et al. A comparative study of diagnostic accuracy in 3 026 pleural biopsies and matched pleural effusion cytology with clinical correlation[J]. Cancer Med, 2023, 12(2):1471-1481.
|
| [17] |
张丽英, 傅冠华, 吴俊琪. 4项血清肿瘤标志物在肺癌辅助诊断和疗效评估中的价值[J]. 检验医学, 2019, 34(4):331-334.
DOI
|
| [18] |
李会萍, 郑大勇, 杨帅, 等. 血清胃泌素释放肽前体在小细胞肺癌中的临床价值[J]. 检验医学, 2020, 35(4):310-313.
DOI
|
| [19] |
陆沈栋, 盛泽波. 肺癌并恶性胸腔积液患者血清和胸腔积液肿瘤标志物水平变化及其对良恶性胸腔积液的鉴别诊断价值研究[J]. 实用心脑肺血管病杂志, 2018, 26(9):38-42.
|
| [20] |
MARCOUX N, GETTINGER S N, O'KANE G,et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas:clinical outcomes[J]. J Clin Oncol, 2019, 37(4):278-285.
|
| [21] |
WANG S, XIE T, HAO X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma[J]. Thorac Cancer, 2021, 12(19):2585-2593.
DOI
PMID
|
| [22] |
ZUGAZAGOITIA J, PAZ-ARES L. Extensive-stage small-cell lung cancer:first-line and second-line treatment options[J]. J Clin Oncol, 2022, 40(6):671-680.
|
| [23] |
TSOU P H, CHIANG P H, LIN Z T, et al. Rapid purification of lung cancer cells in pleural effusion through spiral microfluidic channels for diagnosis improvement[J]. Lab Chip, 2020, 20(21):4007-4015.
|
| [24] |
TIAN F, LIU D, WEI N, et al. Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning[J]. Nat Med, 2024, 30(5):1309-1319.
DOI
PMID
|